EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
1. The EU backed AstraZeneca's Enhertu for breast cancer treatment. 2. This approval targets patients unsuitable for more hormone treatments.
FAQ
Why Bullish?
Enhertu's approval expands AstraZeneca's oncology portfolio, enhancing growth potential and historical revenue boosts seen with new drug approvals.
How important is it?
Enhertu's approval significantly enhances AstraZeneca's oncology offerings, likely impacting sales and investor confidence.
Why Long Term?
The approval solidifies market position and may lead to sustained revenue in oncology, similar to recent successful drug launches.